Nutraceuticals in Lipid-Lowering Treatment: A Narrative Review on the Role of Chitosan

Angiology

Volumn 66, Issue 5, 2015, Pages 416-421

  Patti, Angelo Maria ^a,b   Katsiki, Niki ^c   Nikolic, Dragana ^a   Al Rasadi, Khalid ^d   Rizzo, Manfredi ^a,b  

^a UNIVERSITY OF PALERMO   (Italy)

^b Euro Mediterranean Institute of Science and Technology   (Italy)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d SULTAN QABOOS UNIVERSITY HOSPITAL   (Oman)

Author keywords

chitosan; dietary supplements; lipids; lipoproteins; nutraceuticals

Indexed keywords

CHITOSAN; GLUCOSE; GREEN TEA EXTRACT; INSULIN; LIPOPROTEIN; NUTRACEUTICAL; PHYTOSTEROL; PREBIOTIC AGENT; STANOZOLOL; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; LIPID;

BODY MASS; CARDIOVASCULAR RISK; DIET SUPPLEMENTATION; DIETARY INTAKE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LIPID STORAGE; LIPOPROTEIN BLOOD LEVEL; NONHUMAN; OBESITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; WEIGHT REDUCTION; ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; ANIMAL; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; DIETARY FIBER; DYSLIPIDEMIAS; RISK FACTOR; TREATMENT OUTCOME;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHITOSAN; DIETARY FIBER; DIETARY SUPPLEMENTS; DYSLIPIDEMIAS; HUMANS; HYPOLIPIDEMIC AGENTS; LIPIDS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84928027364     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319714542999     Document Type: Review

References (62)

1. Li JW, Vederas JC. Drug discovery and natural products: end of an era or an endless frontier?. Science. 2009 ; 325 (5937). 161-165
2. Harvey AL. Natural products in drug discovery. Drug Discov Today. 2008 ; 13 (19-20). 894-901
3. Newman DJ. Natural products as leads to potential drugs: an old process or the new hope for drug discovery?. J Med Chem. 2008 ; 51 (9). 2589-2599
4. Potterat O, Hamburger M. Drug discovery and development with plant-derived compounds. Prog Drug Res. 2008 ; 65 (45). 47-118
5. Quinn RJ, Carroll AR, Pham NB, et al. Developing a drug-like natural product library. J Nat Prod. 2008 ; 71 (3). 464-468
6. Chin YW, Balunas MJ, Chai HB, Kinghorn AD. Drug discovery from natural sources. AAPS J. 2006 ; 8 (2). E239 - E253
7. Efange SMN. Natural products: a continuing source of inspiration for the medicinal chemist. In: Iwu MM, Wootton JC, eds. Ethnomedicine and Drug Discovery. Amsterdam: Elsevier Science; 2002:61-69.
8. Hippocrates. Epidemics. Smith WD, ed. Cambridge: Loeb Classical Library, Harvard University Press ; 1994 :
9. Spitaleri G, Toesca A, Botteri E, et al. Breast phyllodes tumor: a review of literature and a single center retrospective series analysis. Crit Rev Oncol Hematol. 2013 ; 88 (2). 427-436
10. Zeichner SB, Harris A, Turner G, Francavilla M, Lutzky J. An acquired factor VIII inhibitor in a patient with HIV and HCV: a case presentation and literature review. Case Rep Hematol. 2013 ; 2013: 628513
11. Baicus A. History of polio vaccination. World J Virol. 2012 ; 1 (4). 108-114
12. Rizzo M, Nikolic D, Banach M, et al. The effects of liraglutide on glucose, inflammatory markers and lipoprotein metabolism: current knowledge and future perspectives. Clin Lipidol. 2013 ; 8 (2). 173-181
13. Rizzo M, Rizvi AA, Spinas GA, Rini GB, Berneis K. Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. Expert Opin Investig Drugs. 2009 ; 18 (10). 1495-1503
14. Ntie-Kang F, Zofou D, Babiaka SB, et al. AfroDb: a select highly potent and diverse natural product library from African medicinal plants. PLoS One. 2013 ; 8 (10). e78085
15. Sahebkar A. Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome?. Biofactors. 2013 ; 39 (2). 197-208
16. Lee IT, Lee WJ, Tsai CM, Su IJ, Yen HT, Sheu WH. Combined extractives of red yeast rice, bitter gourd, chlorella, soy protein, and licorice improve total cholesterol, low-density lipoprotein cholesterol, and triglyceride in subjects with metabolic syndrome. Nutr Res. 2012 ; 32 (2). 85-92
17. Salamone F, Galvano F, Cappello F, Mangiameli A, Barbagallo I, Li Volti G. Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis. Transl Res. 2012 ; 159 (6). 477-486
18. Wang YX, Wang YP, Zhang H, et al. Synthesis and biological evaluation of berberine analogues as novel up-regulators for both low-density-lipoprotein receptor and insulin receptor. Bioorg Med Chem Lett. 2009 ; 19 (21). 6004-6008
19. Scotece M, Gomez R, Conde J, et al. Further evidence for the anti-inflammatory activity of oleocanthal: inhibition of MIP-1alpha and IL-6 in J774 macrophages and in ATDC5 chondrocytes. Life Sci. 2012 ; 91 (23-24). 1229-1235
20. Fogliano V, Sacchi R. Oleocanthal in olive oil: between myth and reality. Mol Nutr Food Res. 2006 ; 50 (1). 5-6
21. Kwak YS, Kyung JS, Kim JS, Cho JY, Rhee MH. Anti-hyperlipidemic effects of red ginseng acidic polysaccharide from Korean red ginseng. Biol Pharm Bull. 2010 ; 33 (3). 468-472
22. Dong H, Zhao Y, Zhao L, Lu F. The effects of berberine on blood lipids: a systemic review and meta-analysis of randomized controlled trials. Planta Med. 2013 ; 79 (6). 437-446
23. Szapary PO, Wolfe ML, Bloedon LT, et al. Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA. 2003 ; 290 (6). 765-772
24. Ebel B, Lemetais G, Beney L, et al. Impact of probiotics on risk factors for cardiovascular diseases. A review. Crit Rev Food Sci Nutr. 2014 ; 54 (2). 175-189
25. Fukuda S, Ohno H. Gut microbiome and metabolic diseases. Semin Immunopathol. 2014 ; 36 (1). 103-114
26. ElnasharMM, ed. Biopolymers. Rijeka, Croatia: Sciyo; 2010:61-80.
27. Yao K, Li J, Yao F, Yin Y, eds. Broken Sound Parkway, FL: CRC Press; Chitosan-Based Hydrogels: Functions and Applications. 2012:2.
28. Gallaher DD, Gallaher CM, Mahrt GJ, et al. A glucomannan and chitosan fiber supplement decreases plasma cholesterol and increases cholesterol excretion in overweight normocholesterolemic humans. J Am Coll Nutr. 2002 ; 21 (5). 428-433
29. Zhang J, Xia W, Liu P, et al. Chitosan modification and pharmaceutical/biomedical applications. Mar Drugs. 2010 ; 8 (7). 1962-87
30. Pittler MH, Ernst E. Dietary supplements for body-weight reduction: a systematic review. Am J Clin Nutr. 2004 ; 79 (4). 529-536
31. Walsh AM, Sweeney T, Bahar B, O'Doherty JV. Multi-functional roles of chitosan as a potential protective agent against obesity. PLoS One. 2013 ; 8 (1). e53828
32. Neyrinck AM, Bindels LB, De Backer F, Pachikian BD, Cani PD, Delzenne NM. Dietary supplementation with chitosan derived from mushrooms changes adipocytokine profile in diet-induced obese mice, a phenomenon linked to its lipid-lowering action. Int Immunopharmacol. 2009 ; 9 (6). 767-773
33. Hsieh YL, Yao HT, Cheng RS, Chiang MT. Chitosan reduces plasma adipocytokines and lipid accumulation in liver and adipose tissues and ameliorates insulin resistance in diabetic rats. J Med Food. 2012 ; 15 (5). 453-460
34. Wang D, Han J, Yu Y, et al. Chitosan oligosaccharide decreases very-low-density lipoprotein triglyceride and increases high-density lipoprotein cholesterol in high-fat-diet-fed rats. Exp Biol Med (Maywood). 2011 ; 236 (9). 1064-1069
35. Liu X, Zhi X, Liu Y, Wu B, Sun Z, Shen J. Effect of chitosan, O-carboxymethyl chitosan, and N-[(2-hydroxy-3-N,N-dimethylhexadecyl ammonium)propyl] chitosan chloride on overweight and insulin resistance in a murine diet-induced obesity. J Agric Food Chem. 2012 ; 60 (13). 3471-3476
36. Xu G, Huang X, Qiu L, Wu J, Hu Y. Mechanism study of chitosan on lipid metabolism in hyperlipidemic rats. Asia Pac J Clin Nutr. 2007 ; 16(suppl 1): 313-317
37. Zhou GD, Li MR, Zhang J, et al. Chitosan ameliorates the severity of steatohepatitis induced by high fat diet in rats. Scand J Gastroenterol. 2008 ; 43 (11). 1371-1377
38. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Metabolic syndrome and non-cardiac vascular diseases: an update from human studies. Curr Pharm Des. 2014 ; 20 (31). 4944-4952
39. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview. Curr Vasc Pharmacol. 2014 ; 12 (4). 627-641
40. Montalto G, Rizzo M, Mikhailidis DP. Managing the cardiovascular risk associated with the metabolic syndrome [published online December 5, 2013]. Curr Pharm Des. 2013 ;:
41. Athyros VG, Katsiki N, Karagiannis A. Nonalcoholic fatty liver disease and severity of cardiovascular disease manifestations. Angiology. 2013 ; 64 (8). 572-575
42. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk?. Curr Vasc Pharmacol. 2011 ; 9 (6). 698-705
43. Ausar SF, Morcillo M, Leon AE, et al. Improvement of HDL- and LDL-cholesterol levels in diabetic subjects by feeding bread containing chitosan. J Med Food. 2003 ; 6 (4). 397-399
44. Rizzo M, Giglio RV, Nikolic D, et al. Effects of chitosan on plasma lipids and lipoproteins: a 4-month prospective pilot study. Angiology. 2013 ; 65 (6). 538-542
45. Ray SD. Potential aspects of chitosan as pharmaceutical excipient. Acta Pol Pharm. 2011 ; 68 (5). 619-622
46. Nikolic D, Katsiki N, Montalto G, Isenovic E, Mikhailidis D, Rizzo M. Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients. 2013 ; 5 (3). 928-948
47. Mikhailidis DP, Elisaf M, Rizzo M, et al. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol. 2011 ; 9 (5). 531-532
48. Mikhailidis DP, Elisaf M, Rizzo M, et al. European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol. 2011 ; 9 (5). 533-571
49. Oravec S, Dukat A, Gavornik P, et al. Atherogenic versus non-atherogenic lipoprotein profiles in healthy individuals. Is there a need to change our approach to diagnosing dyslipidemia?. Curr Med Chem. 2014 ; 21 (25). 2892-2901
50. Jaffer S, Sampalis JS. Efficacy and safety of chitosan HEP-40 in the management of hypercholesterolemia: a randomized, multicenter, placebo-controlled trial. Altern Med Rev. 2007 ; 12 (3). 265-273
51. Choi CR, Kim EK, Kim YS, et al. Chitooligosaccharides decreases plasma lipid levels in healthy men. Int J Food Sci Nutr. 2012 ; 63 (1). 103-106
52. Mekhail M, Tabrizian M. Injectable chitosan-based scaffolds in regenerative medicine and their clinical translatability. Adv Healthc Mater. 2014 ; 3 (10). 1529-1545
53. Jung MH, Seong PN, Kim MH, Myong NH, Chang MJ. Effect of green tea extract microencapsulation on hypertriglyceridemia and cardiovascular tissues in high fructose-fed rats. Nutr Res Pract. 2013 ; 7 (5). 366-372
54. Aziz MT, El Ibrashy IN, Mikhailidis DP, et al. Signaling mechanisms of a water soluble curcumin derivative in experimental type 1 diabetes with cardiomyopathy. Diabetol Metab Syndr. 2013 ; 5 (1). 13
55. Liu CY, Huang CJ, Huang LH, Chen IJ, Chiu JP, Hsu CH. Effects of green tea extract on insulin resistance and glucagon-like peptide 1 in patients with type 2 diabetes and lipid abnormalities: a randomized, double-blinded, and placebo-controlled trial. PLoS One. 2014 ; 9 (3). e91163
56. Kellow NJ, Coughlan MT, Reid CM. Metabolic benefits of dietary prebiotics in human subjects: a systematic review of randomised controlled trials. Br J Nutr. 2014 ; 111 (7). 1147-1161
57. Rondanelli M, Monteferrario F, Faliva MA, Perna S, Antoniello N. Key points for maximum effectiveness and safety for cholesterol-lowering properties of plant sterols and use in the treatment of metabolic syndrome. J Sci Food Agric. 2013 ; 93 (11). 2605-2610
58. Rizzo M, Berneis K, Koulouris S, et al. Should we measure routinely oxidised and atherogenic dense low-density lipoproteins in subjects with type 2 diabetes?. Int J Clin Pract. 2010 ; 64 (12). 1632-1142
59. Bays HE, Evans JL, Maki KC, et al. Chitin-glucan fiber effects on oxidized low-density lipoprotein: a randomized controlled trial. Eur J Clin Nutr. 2013 ; 67 (1). 2-7
60. Andersson U, Berger K, Hogberg A, Landin-Olsson M, Holm C. Effects of rose hip intake on risk markers of type 2 diabetes and cardiovascular disease: a randomized, double-blind, cross-over investigation in obese persons. Eur J Clin Nutr. 2012 ; 66 (5). 585-590
61. Ruscica M, Gomaraschi M, Mombelli G, et al. Nutraceutical approach to moderate cardiometabolic risk: results of a randomized, double-blind and crossover study with Armolipid plus. J Clin Lipidol. 2014 ; 8 (1). 61-68
62. Soare A, Weiss EP, Holloszy JO, Fontana L. Multiple dietary supplements do not affect metabolic and cardio-vascular health. Aging (Albany NY). 2014 ; 6 (2). 149-157